Consun Pharmaceutical Group Limited reported no changes in its share structure for the month ended 30 April 2026, according to the company’s latest monthly return filed with the Hong Kong Stock Exchange on 4 May 2026.

• Authorised share capital remained at 5.00 billion ordinary shares with a par value of HKD 0.10, equivalent to HKD 500.00 million.

• Issued share capital was unchanged at 841.55 million shares, with no treasury shares outstanding or cancelled during the period.

• The company confirmed compliance with the Main Board’s 25% minimum public-float requirement as at month-end.

Share-based Incentives

• 2013 Share Option Scheme: 7.07 million options were outstanding, with no exercises, cancellations, or new grants in April.

• 2024 Share Option Scheme: no options were outstanding, while the scheme’s unutilised limit allows issuance of up to 84.28 million shares.

No warrants, convertible securities, or other equity arrangements were reported for the month. The filing was signed by Company Secretary Gao Haien, confirming all regulatory requirements were met.